The patent includes both structure and method claims for inducing neurogenesis and the growth of new neurons, both in-vitro and in-vivo.
Neuralstem announces Notice of Allowance for two additional neurogenic compound patents.
The company’s first neurogenic patented compound, NSI-189 is currently in a Phase I FDA-approved safety trial in major depressive disorder.
The Phase Ib portion of the trial, in depressed patients, is likely to begin this fall .